Aldeyra Therapeutics, Inc. 137.F Stock
Aldeyra Therapeutics, Inc. Price Chart
Aldeyra Therapeutics, Inc. 137.F Financial and Trading Overview
| Aldeyra Therapeutics, Inc. stock price | 3.67 EUR |
| Previous Close | 10.83 EUR |
| Open | 9.83 EUR |
| Bid | 9.8 EUR x 31400 |
| Ask | 9.93 EUR x 30200 |
| Day's Range | 9.83 - 9.83 EUR |
| 52 Week Range | 2.96 - 11.13 EUR |
| Volume | 430 EUR |
| Avg. Volume | 283 EUR |
| Market Cap | 575.81M EUR |
| Beta (5Y Monthly) | 1.117957 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.47 EUR |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 25.45 EUR |
137.F Valuation Measures
| Enterprise Value | 409.32M EUR |
| Trailing P/E | N/A |
| Forward P/E | -8.057377 |
| PEG Ratio (5 yr expected) | -0.12 |
| Price/Sales (ttm) | N/A |
| Price/Book (mrq) | 4.2116537 |
| Enterprise Value/Revenue | N/A |
| Enterprise Value/EBITDA | -6.524 |
Trading Information
Aldeyra Therapeutics, Inc. Stock Price History
| Beta (5Y Monthly) | 1.117957 |
| 52-Week Change | 205.54% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 11.13 EUR |
| 52 Week Low | 2.96 EUR |
| 50-Day Moving Average | 9.13 EUR |
| 200-Day Moving Average | 6.77 EUR |
137.F Share Statistics
| Avg. Volume (3 month) | 283 EUR |
| Avg. Daily Volume (10-Days) | 479 EUR |
| Shares Outstanding | 58.58M |
| Float | 35.81M |
| Short Ratio | N/A |
| % Held by Insiders | 2.75% |
| % Held by Institutions | 60.07% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | 0% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -20.14% |
| Return on Equity (ttm) | -37.11% |
Income Statement
| Revenue (ttm) | N/A |
| Revenue Per Share (ttm) | N/A |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | N/A |
| EBITDA | -62736620 EUR |
| Net Income Avi to Common (ttm) | -60852024 EUR |
| Diluted EPS (ttm) | -0.96 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 165.03M EUR |
| Total Cash Per Share (mrq) | 2.82 EUR |
| Total Debt (mrq) | 16.11M EUR |
| Total Debt/Equity (mrq) | 11.74 EUR |
| Current Ratio (mrq) | 10.496 |
| Book Value Per Share (mrq) | 2.334 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -53207808 EUR |
| Levered Free Cash Flow (ttm) | 36.56M EUR |
Profile of Aldeyra Therapeutics, Inc.
| Country | Germany |
| State | MA |
| City | Lexington |
| Address | 131 Hartwell Avenue |
| ZIP | 02421 |
| Phone | 781 761 4904 |
| Website | https://www.aldeyra.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 15 |
Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases. The company also develops ADX-629, an orally administered RASP modulator for treatment of COVID-19, atopic asthma, psoriasis, and alcohol intoxication; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment primary vitreoretinal lymphoma cancer, proliferative vitreoretinopathy, and retinitis pigmentosa, as well as rare retinal diseases characterized by inflammation and vision loss. In addition, it develops ADX-246 in systemic immune-mediated disease; and ADX-248 in geographic atrophy. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.
Q&A For Aldeyra Therapeutics, Inc. Stock
What is a current 137.F stock price?
Aldeyra Therapeutics, Inc. 137.F stock price today per share is 3.67 EUR.
How to purchase Aldeyra Therapeutics, Inc. stock?
You can buy 137.F shares on the Frankfurt exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Aldeyra Therapeutics, Inc.?
The stock symbol or ticker of Aldeyra Therapeutics, Inc. is 137.F.
Which industry does the Aldeyra Therapeutics, Inc. company belong to?
The Aldeyra Therapeutics, Inc. industry is Biotechnology.
How many shares does Aldeyra Therapeutics, Inc. have in circulation?
The max supply of Aldeyra Therapeutics, Inc. shares is 61M.
What is Aldeyra Therapeutics, Inc. Price to Earnings Ratio (PE Ratio)?
Aldeyra Therapeutics, Inc. PE Ratio is now.
What was Aldeyra Therapeutics, Inc. earnings per share over the trailing 12 months (TTM)?
Aldeyra Therapeutics, Inc. EPS is -0.47 EUR over the trailing 12 months.
Which sector does the Aldeyra Therapeutics, Inc. company belong to?
The Aldeyra Therapeutics, Inc. sector is Healthcare.